Accuray Incorporated (NASDAQ:ARAY) CEO Joshua Levine sold 15,839 shares of the firm’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $4.00, for a total value of $63,356.00. Following the completion of the transaction, the chief executive officer now directly owns 1,340,197 shares in the company, valued at $5,360,788. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Joshua Levine also recently made the following trade(s):
- On Monday, November 5th, Joshua Levine acquired 25,000 shares of Accuray stock. The stock was bought at an average cost of $4.75 per share, for a total transaction of $118,750.00.
- On Wednesday, October 31st, Joshua Levine sold 18,742 shares of Accuray stock. The shares were sold at an average price of $4.69, for a total value of $87,899.98.
- On Wednesday, October 3rd, Joshua Levine sold 17,242 shares of Accuray stock. The shares were sold at an average price of $4.38, for a total value of $75,519.96.
NASDAQ:ARAY traded down $0.15 during mid-day trading on Friday, hitting $3.78. The company had a trading volume of 18,987 shares, compared to its average volume of 581,685. The company has a debt-to-equity ratio of 2.74, a current ratio of 1.69 and a quick ratio of 0.96. Accuray Incorporated has a 1 year low of $3.20 and a 1 year high of $6.15. The firm has a market capitalization of $344.04 million, a PE ratio of -13.61 and a beta of 1.51.
Accuray (NASDAQ:ARAY) last announced its earnings results on Tuesday, October 30th. The medical equipment provider reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The business had revenue of $95.83 million for the quarter, compared to analyst estimates of $95.10 million. Accuray had a negative net margin of 5.79% and a negative return on equity of 42.24%. During the same quarter in the prior year, the business earned ($0.11) earnings per share. Equities analysts anticipate that Accuray Incorporated will post -0.14 EPS for the current year.
Several research analysts have commented on the company. BidaskClub lowered Accuray from a “sell” rating to a “strong sell” rating in a research report on Friday, August 17th. Citigroup cut their price objective on Accuray from $4.00 to $3.50 and set a “sell” rating on the stock in a research report on Friday, August 17th. BTIG Research reissued a “hold” rating on shares of Accuray in a research report on Wednesday, August 22nd. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $6.00 price objective on shares of Accuray in a research report on Friday, August 17th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. Accuray has a consensus rating of “Hold” and an average target price of $5.63.
Several institutional investors have recently made changes to their positions in the company. First Trust Advisors LP grew its stake in shares of Accuray by 113.1% during the second quarter. First Trust Advisors LP now owns 27,337 shares of the medical equipment provider’s stock valued at $112,000 after acquiring an additional 14,508 shares in the last quarter. Northern Trust Corp grew its stake in Accuray by 1.5% in the second quarter. Northern Trust Corp now owns 1,043,016 shares of the medical equipment provider’s stock worth $4,276,000 after purchasing an additional 15,117 shares in the last quarter. California Public Employees Retirement System grew its stake in Accuray by 37.5% in the second quarter. California Public Employees Retirement System now owns 75,522 shares of the medical equipment provider’s stock worth $310,000 after purchasing an additional 20,600 shares in the last quarter. Bank of America Corp DE grew its stake in Accuray by 11.0% in the second quarter. Bank of America Corp DE now owns 216,507 shares of the medical equipment provider’s stock worth $888,000 after purchasing an additional 21,391 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd grew its stake in Accuray by 110.2% in the third quarter. Dynamic Technology Lab Private Ltd now owns 42,993 shares of the medical equipment provider’s stock worth $193,000 after purchasing an additional 22,544 shares in the last quarter. Institutional investors own 84.28% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Accuray Incorporated (ARAY) CEO Joshua Levine Sells 15,839 Shares of Stock” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/12/07/accuray-incorporated-aray-ceo-joshua-levine-sells-15839-shares-of-stock.html.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
See Also: Cash Flow
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.